The agreed merger of Pfizer Inc. and Wyeth is another example of continued consolidation within the pharmaceutical industry, says Robert Taketomo, PharmD, president and CEO of Ventegra in La Jolla, Calif.
“[This move] is consistent with Pfizer’s goal of remaining one of the largest—if not the largest—pharma company,” Taketomo says. “The question is how such consolidation will impact the competitive and innovative nature of the industry.”
The combination with Wyeth advances strategic priorities Pfizer has identified and pursued over the last two years including:
Many analysts believe the merger would do little to buoy Pfizer or help it develop new blockbuster drugs. The new combined portfolio could help lessen the blow when Lipitor goes off patent, however. Pfizer will gain Wyeth’s Prevnar vaccine for childhood infections and Enbrel rheumatoid arthritis treatment.